SCHEMBL6882285

SCHEMBL6882285

NCCC(C(=O)O)P(=O)(O)O

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 4/20 0.61
GABRR1 P24046 2/20 0.44
LMNA P02545 1/20 0.42
CYP3A4 P08684 1/20 0.42
NFKB1 P19838 1/20 0.42
BLM P54132 1/20 0.42
PMP22 Q01453 1/20 0.42
GABBR2 O75899 1/20 0.41
GABBR1 Q9UBS5 1/20 0.41
ALDH1A1 P00352 1/20 0.40
GLUL P15104 1/20 0.39
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38
NAALAD2 Q9Y3Q0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4726591 0.86 FOLH1 (0.57) FOLH1LMNACYP3A4NFKB1BLM
SCHEMBL10587263 0.82 GABBR2 (0.54) FOLH1GABRR1LMNABLMGABBR2
Ammonia Solution, Strong SCHEMBL10491234 0.80 GABBR2 (0.52) FOLH1GABRR1LMNABLMGABBR2
SCHEMBL10624719 0.80 FOLH1 (0.67) FOLH1LMNABLMGLULNAALAD2
SCHEMBL8674489 0.80 FOLH1 (0.54) FOLH1LMNABLMGABBR2GABBR1
SCHEMBL10702069 0.78 FOLH1 (0.64) FOLH1LMNABLMGLULGRIN2D
SCHEMBL11294536 0.78 FOLH1 (0.64) FOLH1ALDH1A1GLULNAALAD2
SCHEMBL9115882 0.77 FOLH1 (0.42) FOLH1GABRR1LMNACYP3A4NFKB1
SCHEMBL2905376 0.76 FOLH1 (0.61) FOLH1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL2201753 0.76 FOLH1 (1.00) FOLH1GRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825211-B1 GLUTAMATE RECEPTORS PLAY A ROLE IN NUMEROUS NEUROLOGICAL, NEURODEGENERATIVE, PSYCHIATRIC, AND PSYCHOLOGICAL DISORDERS GEORGETOWN UNIVERSITY 2004-11-30 US disclosed
US-6610743-B2 Central nervous system disorders GEORGETOWN UNIVERSITY 2003-08-26 US disclosed
US-20020165200-A1 Bicyclic metabotropic glutamate receptor ligands NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-11-07 US disclosed
US-6376532-B2 NEUROTRANSMITTER GEORGETOWN UNIVERSITY 2002-04-23 US disclosed
US-20010018429-A1 Neurotransmitter NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2001-08-30 US disclosed
US-6204292-B1 TREATMENT OF NEUROLOGICAL, NEURODEGENERATIVE, PSYCHIATRIC AND PSYCHOLOGICAL DISORDERS. GEORGETOWN UNIVERSITY 2001-03-20 US disclosed
EP-1000015-A1 BICYCLIC METABOTROPIC GLUTAMATE RECEPTOR LIGANDS GEORGETOWN UNIVERSITY (US) 2000-05-17 EP disclosed
WO-1999003822-A9 BICYCLIC METABOTROPIC GLUTAMATE RECEPTOR LIGANDS UNIV GEORGETOWN (US) 1999-04-29 WO disclosed
WO-1999003822-A1 BICYCLIC METABOTROPIC GLUTAMATE RECEPTOR LIGANDS GEORGETOWN UNIVERSITY (US) 1999-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165200-A1 Bicyclic metabotropic glutamate receptor ligands GRM3, GRM1, GRM2 FOLH1 329/4885GABRR1 51/4885LMNA 4813/4885
US-20010018429-A1 Neurotransmitter GRM3, GRM1, GRM2 FOLH1 427/4885GABRR1 72/4885LMNA 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.